Obesity‑drug market moves from scarcity to competition
Eli Lilly launched its oral obesity drug Foundayo priced from about $149 a month, kicking off a more direct commercial fight with Novo Nordisk and others. (biopharmadive.com) Meanwhile loss of semaglutide patent protection in India has triggered a wave of generics that are already reshaping local markets and denting Lilly’s sales there. (bloomberg.com)
A weight-loss drug that used to feel like a sold-out concert ticket is starting to look more like a supermarket aisle. On April 9, Eli Lilly put its new obesity pill Foundayo on sale in the United States at a starter price of $149 a month for people paying cash, matching the starter price Novo Nordisk set for its Wegovy pill. (biopharmadive.com) That price fight is new because the first phase of this market was mostly about shortages and waiting lists. The next phase is about who can make the easier pill, who can get it onto Amazon and telehealth sites fastest, and who can keep patients from switching after the first month. (biopharmadive.com) Novo Nordisk got to this round first. The Food and Drug Administration approved the Wegovy pill in December 2025, and Novo launched it in the United States in early January 2026, giving it roughly a three-month head start before Foundayo arrived. (novonordisk-us.com, biopharmadive.com, finance.yahoo.com) The two pills are selling two different promises. Wegovy’s pitch is stronger weight-loss data, while Foundayo’s pitch is convenience: Lilly says Foundayo can be taken any time of day without food or water rules, while Novo says the Wegovy pill has to be taken in the morning on an empty stomach and then followed by a 30-minute wait before food, drinks, or other medicines. (biopharmadive.com, foundayo.lilly.com, wegovy.com) The clinical numbers help explain that split. In the trials cited around approval, Foundayo produced about 11% average weight loss in adults with obesity without diabetes at its highest dose, while Novo has pointed to about 14% average weight loss for the Wegovy pill, though the two drugs were not tested head-to-head in the same study. (biopharmadive.com) Lilly is coming into this pill fight from a position of strength in injections. BioPharma Dive reported that Lilly’s tirzepatide franchise, sold as Zepbound for obesity and Mounjaro for diabetes, topped $36 billion in sales last year after taking share from Novo’s older Wegovy and Ozempic franchise. (biopharmadive.com) The pricing ladder shows how much the companies want new patients, not just each other’s patients. Lilly says some insured patients can get the Foundayo starter dose for $25 a month, while its injected obesity drug Zepbound still starts at $299 a month for uninsured self-pay users, which makes the pill look like the cheaper on-ramp. (biopharmadive.com, zepbound.lilly.com) Washington is also pushing the market toward volume. The Centers for Medicare & Medicaid Services says a temporary Medicare Glucagon-Like Peptide-1 Bridge begins in July 2026, and the White House said last November that Wegovy, Zepbound, Ozempic, and Mounjaro would be available to some Medicare patients at $245 a month under a separate pricing deal. (cms.gov, whitehouse.gov) The more revealing price war may be happening outside the United States. In India, Novo’s semaglutide compound lost patent protection on March 20, 2026, and Bloomberg reported that at least five big Indian drugmakers were preparing copies that could sell for about $14. (bloomberg.com, bloomberg.com) Those copies are already changing who wins and loses. Bloomberg reported on April 9 that cheap semaglutide generics in India are cutting into Eli Lilly’s early lead there, giving the rest of the world a preview of what happens when obesity drugs stop being scarce patented brands and start becoming a crowded market with lookalikes at a fraction of the price. (bloomberg.com)
